Homepage
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Zevra Therapeutics, Inc. (ZVRA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Biotechnology
Boston, MA 02110, United States
zevra.com
Price
$9.64
Market Cap
$569.9M
Employees
61
Beta
0.85
Avg Volume
1,551,033
CEO
Mr. Neil F. McFarlane
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treatments for rare diseases. The company concentrates on rare neurological and sleep-related conditions, including certain urea cycle disorders, Niemann-Pick disease type C, and idiopathic hypersomnia. Zevra Therapeutics develops and commercializes therapies aimed at patient populations with limited or no existing treatment options, emphasizing data-driven development and close alignment with patient needs. In addition to its internal pipeline, the company participates in the rare disease market through royalty revenue associated with AZSTARYS, an attention-deficit/hyperactivity disorder (ADHD) treatment marketed by a commercial partner. Headquartered in Celebration, Florida and founded in 2006, Zevra Therapeutics operates within the broader health technology and pharmaceuticals industry, serving specialized healthcare providers, treatment centers, and patients affected by complex, underserved conditions. Its role in the market is defined by a focus on niche indications where regulatory pathways and clinical development require targeted expertise and close collaboration with the rare disease community.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Jul 30 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was May 6, 2026.
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| May 6, 2026 | $0.08 | $0.18 +125.0% | — | — |
| Mar 19, 2026 | $0.16 | $0.17 +6.3% | — | — |
| Mar 9, 2026 | $0.05 | $0.19 +280.0% | — | — |
| Nov 5, 2025 | $-0.02 | $-0.01 +50.0% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Jul 8, 2026 | 144 | View |
| Jun 23, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 18, 2026 | 4 | View |
| Jun 5, 2026 | 8-K | View |
| May 29, 2026 | 4 | View |
| May 13, 2026 | 4 | View |
| May 11, 2026 | 144 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Jul 31, 2026 1:12am (just now)
Current data · timestamped when a report runs
$9.64
Change · Jul 31
-0.14 (-1.43%)
Day Range
$9.50 – $9.87
52-Week Range
$7.16 – $15.04
50-Day MA
$12.20
200-Day MA
$10.12
Volume
1,912,634.00
Share Structure
Outstanding
59,114,850.00
Float
54,926,189.00
Free Float
92.9%
High free float
— 92.9% of shares trade freely, ~7.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
7.14
Stock Price: $9.64
EPS (Diluted): 1.35
EPS (Diluted): 1.35
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
3.57
Stock Price: $9.64
Total Equity: $154.66M
Shares: 57,262,715
Total Equity: $154.66M
Shares: 57,262,715
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
-9.81
Market Cap: $569.87M
Total Debt: $61.93M
Cash: $62.41M
EBITDA: -$58.89M
Total Debt: $61.93M
Cash: $62.41M
EBITDA: -$58.89M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$577.7M
Market Cap: $569.87M
Total Debt: $61.93M
Cash: $62.41M
Total Debt: $61.93M
Cash: $62.41M
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
84.5%
Gross Profit: $89.99M
Revenue: $106.47M
Revenue: $106.47M
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
-59.1%
Operating Income: -$62.94M
Revenue: $106.47M
Revenue: $106.47M
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
78.2%
Net Income: $83.23M
Revenue: $106.47M
Revenue: $106.47M
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
53.8%
Net Income: $83.23M
Total Equity: $154.66M
Total Equity: $154.66M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-39.2%
Operating Income: -$62.94M
Tax Rate: 4.0%
Equity: $154.66M
Total Debt: $61.93M
Cash: $62.41M
Tax Rate: 4.0%
Equity: $154.66M
Total Debt: $61.93M
Cash: $62.41M
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
5.68
Current Assets: $223.01M
Current Liabilities: $39.28M
Current Liabilities: $39.28M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.40
Short-Term Debt: $0.00
Long-Term Debt: $61.93M
Total Debt: $61.93M
Total Equity: $154.66M
Long-Term Debt: $61.93M
Total Debt: $61.93M
Total Equity: $154.66M
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$1.86
Revenue: $106.47M
Shares: 57,262,715
Shares: 57,262,715
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$2.70
Total Equity: $154.66M
Shares: 57,262,715
Shares: 57,262,715
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-0.04
Operating CF: -$1.60M
CapEx: -$835,000
Shares: 57,262,715
CapEx: -$835,000
Shares: 57,262,715
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $9.64
Stock Price: $9.64
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $83.23M
Net Income: $83.23M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Jul 30, 2026 11:49am (13h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $28.7M | $10.5M | $27.5M | $23.6M | $106.5M |
| Cost of Revenue | — | — | $2.2M | $7.4M | $16.5M |
| Gross Profit | — | — | $25.3M | $16.2M | $90.0M |
| Operating Expenses | — | — | $74.9M | $103.2M | $152.9M |
| Operating Income | $7.7M | -$42.5M | -$49.6M | -$87.0M | -$62.9M |
| Net Income | -$8.6M | -$41.5M | -$46.0M | -$105.5M | $83.2M |
| EBITDA | $8.0M | -$41.6M | -$48.6M | -$80.6M | -$58.9M |
| EPS | $-2.11 | $-1.20 | $-1.30 | $-2.28 | $1.40 |
| EPS (Diluted) | $-2.11 | — | — | $-2.28 | $1.35 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 11:49am (13h ago)| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $65.5M | — | $43.0M | $33.8M | $62.4M |
| Total Current Assets | $93.0M | — | $86.9M | $86.0M | $223.0M |
| Total Assets | $115.5M | — | $172.3M | $178.1M | $284.7M |
| Current Liabilities | $11.7M | — | $73.7M | $34.1M | $39.3M |
| Long-Term Debt | — | — | $5.1M | $59.5M | $61.9M |
| Total Liabilities | $29.7M | — | $110.5M | $138.5M | $130.1M |
| Total Equity | $85.8M | $61.5M | $61.9M | $39.7M | $154.7M |
| Retained Earnings | -$308.6M | — | -$399.8M | -$505.3M | -$422.1M |
Cash Flow (Annual)
Last updated: Jul 30, 2026 11:49am (13h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $10.4M | -$18.7M | -$33.5M | -$69.7M | -$1.6M |
| Capital Expenditure | $-102,000 | $-93,000 | $-296,000 | $0 | $-835,000 |
| Free Cash Flow | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.4M |
| Acquisitions (net) | $0 | -$14.1M | -$30.4M | $0 | — |
| Net Debt Issued / (Repaid) | $0 | $12.8M | $24.9M | $16.3M | $0 |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.8M | -$4.7M | -$3.4M | $0 | — |
| Net Change in Cash | $108.0M | -$46.9M | -$22.4M | -$9.3M | $28.6M |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 11:49am (13h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -63.5% | +162.6% | -14.0% | +350.9% |
| Gross Profit Growth | — | — | -36.0% | +455.7% |
| Operating Income Growth | -649.9% | -16.7% | -75.4% | +27.7% |
| Net Income Growth | -385.6% | -10.8% | -129.1% | +178.9% |
| EBITDA Growth | -620.4% | -16.9% | -65.9% | +26.9% |
Industry Benchmarks
Compares ZVRA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ZVRA — it's generated by the pipeline (
market-narrative step).
Claude Findings
No AI findings yet for ZVRA — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for ZVRA — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for ZVRA — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
Ten long-horizon business-character traits the Quality / Value / Sentiment lenses don’t break out, scored 1–10.
No scorecard yet for ZVRA — the ten traits are scored by the
pipeline (
ext-scorecard step) when a report is run on this ticker.
No community reviews yet for ZVRA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.499 · 31c8b2f7 · 2026-07-30 18:34:04